Merrion Pharmaceuticals is a publicly listed product development company focused on delivering innovation to the market by: designing our own patented products and partnering with other pharmaceutical companies to develop patented products. Established in 2003, Merrion are engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion Pharmaceutical's patented drug delivery technology (GIPET®) hugely increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. As well as increasing absorption, Merrion's Technology also increases the consistency of absorption. These new products can provide substantial benefits in enhanced drug efficacy, improved safety, toxicity and side effect profile, health economics, patient experience and quality of life. Merrion is listed on the Irish Stock Exchange (ESM) under the symbol MERR.
